HALO (STOCKS)
Halozyme Therapeutics, Inc.
$66.637900
-1.182100 (-1.74%)
Prev close: $67.820000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,935.41M
- Employees
- 350
- P/E (TTM)
- 26.52
- P/B (TTM)
- 163.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
9
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.24 | $2.24 | -2.4820 | -110.70% |
|
Sep 2025 (Q3)
|
$1.72 | $1.66 | +0.0591 | +3.56% |
|
Jun 2025 (Q2)
|
$1.54 | $1.29 | +0.2487 | +19.26% |
|
Mar 2025 (Q1)
|
$1.11 | $0.97 | +0.1430 | +14.79% |
Financial Statements
| Revenues | $1.40B |
| Benefits Costs and Expenses | $929.74M |
| Cost Of Revenue | $228.77M |
| Costs And Expenses | $927.61M |
| Gross Profit | $1.17B |
| Operating Expenses | $698.83M |
| Selling, General, and Administrative Expenses | $207.09M |
| Other Operating Expenses | $491.74M |
| Operating Income/Loss | $469.01M |
| Income/Loss From Continuing Operations After Tax | $316.89M |
| Income/Loss From Continuing Operations Before Tax | $466.88M |
| Income Tax Expense/Benefit | $149.99M |
| Net Income/Loss | $316.89M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $316.89M |
| Net Income/Loss Available To Common Stockholders, Basic | $316.89M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.64 |
| Diluted Earnings Per Share | $2.56 |
| Basic Average Shares | 119,840,000 |
| Diluted Average Shares | 123,904,000 |
| Assets | $2.53B |
| Current Assets | $825.21M |
| Inventory | $176.48M |
| Prepaid Expenses | $71.93M |
| Other Current Assets | $576.81M |
| Noncurrent Assets | $1.70B |
| Fixed Assets | $44.44M |
| Intangible Assets | $981.47M |
| Other Non-current Assets | $674.21M |
| Liabilities | $2.48B |
| Current Liabilities | $177.09M |
| Accounts Payable | $20.90M |
| Other Current Liabilities | $156.19M |
| Noncurrent Liabilities | $2.30B |
| Long-term Debt | $2.14B |
| Other Non-current Liabilities | $156.79M |
| Equity | $48.81M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $48.81M |
| Liabilities And Equity | $2.53B |
| Net Cash Flow From Operating Activities | $651.56M |
| Net Cash Flow From Operating Activities, Continuing | $651.56M |
| Net Cash Flow From Investing Activities | -$545.81M |
| Net Cash Flow From Investing Activities, Continuing | -$545.81M |
| Net Cash Flow From Financing Activities | -$85.17M |
| Net Cash Flow From Financing Activities, Continuing | -$85.17M |
| Net Cash Flow | $20.57M |
| Net Cash Flow, Continuing | $20.57M |
| Comprehensive Income/Loss | $294.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $294.97M |
| Other Comprehensive Income/Loss | $294.97M |